{"id":"W2885286334","doi":"10.1158/1538-7445.am2018-ct075","title":"Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Sunnybrook Health Science Centre; Centre Intégré de Santé et de Services Sociaux des Laurentides; Health Sciences Centre; Santé Montérégie","funders":"","keywords":"Carboplatin; Medicine; Pembrolizumab; Placebo; Internal medicine; Oncology; Pemetrexed; Tolerability; Nausea; Population; Interim analysis; Cisplatin; Clinical trial; Chemotherapy; Cancer; Adverse effect; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002432574,0.002274707,0.002921012,0.0006232134,0.0006904385,0.001490325,0.001740631,0.002144899,0.01489221],"category_scores_gemma":[0.001708901,0.000993298,0.001654695,0.0005165479,0.001618168,0.001447603,0.0004883313,0.004228647,0.002291208],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001241091,"about_ca_system_score_gemma":0.002494235,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001302875,"about_ca_topic_score_gemma":0.003169136,"domain_scores_codex":[0.9992749,0.0004012112,0.00004627406,0.0001111385,0.00005820408,0.0001082646],"domain_scores_gemma":[0.9990973,0.00019167,0.0002280161,0.00008271344,0.00006035445,0.0003399158],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9752795,0.01004803,0.0002086557,0.0005590418,0.0003822508,0.00003476513,0.00002956817,0.0002254514,0.005549252,0.0001306964,0.001644152,0.005908681],"study_design_scores_gemma":[0.957941,0.0404114,0.0004115198,0.00001554609,0.0001313161,0.00001876005,0.000006676082,0.0001834941,0.0004346711,0.00006393322,0.0003738489,0.000007846956],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9555268,0.003847918,0.001749819,0.001430464,0.001166481,0.02374501,0.006555125,0.0006572664,0.005321112],"genre_scores_gemma":[0.9595676,0.002656309,0.00352649,0.002574236,0.0008071422,0.01869613,0.004311137,0.00009810291,0.007762869],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01489221,"threshold_uncertainty_score":0.04981947,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2024246459460501,"score_gpt":0.4864854517590442,"score_spread":0.2840608058129941,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}